Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State (Nebuadom)

NCT02103374 Phase 4 COMPLETED

Design studies of nebulization in COPD does not respond adequately to the clinically relevant question: the intervention of administering nebulized bronchodilators at home it is likely to make a profit, compared to the standard optimized treatment as defined by the recommendations of the SPLF, patients with severe COPD (stage III, FEV between 30% and 50% of the theoretical value) and very severe (stage IV, less than 30% of the theoretical value FEV)? The concept of profit in this context is based on criteria of dyspnea, quality of life, use of health system (exacerbations, hospitalizations, prescription of antibiotics and steroids ...).

Details

Lead sponsor	University Hospital, Tours
Phase	Phase 4
Status	COMPLETED
Enrolment	45
Start date	2012-01
Completion	2015-12

Conditions

• Severe Chronic Obstructive Pulmonary Disease

Interventions

• Atrovent + Bricanyl or Atrovent + Ventoline
• Placebo

Primary outcomes

• Score for quality of life, assessed by the questionnaire St Georges — Patients will be followed for the duration of their participation ie 48 weeks

Countries

France